Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma

Autor: Sébastien Salas, Suzanne Monjanel-Mouterde, Alain Durand, Cédric Mercier, Roger Favre, Charlotte Dupuis, Chenguang Yang, Marjorie Baciuchka-Palmaro, Joseph Ciccolini, Bruno Lacarelle, Bertrand Pourroy, Raphaelle Fanciullino, Medhi Balti, Florence Duffaud, Brigitte Tranchand

Publikováno v: Therapeutic Drug Monitoring
Therapeutic Drug Monitoring, 2006, 28(4), pp.532-9
Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2006, 28(4), pp.532-9

Cisplatin (CDDP) is an anticancer agent widely used in testicular cancer, for which pharmacokinetic (PK)/pharmacodynamic relationships have usually been based upon measurement of its unbound fraction in plasma. Because it has been shown that free CDD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2284e7f1285f5a867189e9d4817659a3
https://pubmed.ncbi.nlm.nih.gov/16885721